Chengdu Pukang Weixin Biotechnology

Chengdu Pukang Weixin Biotechnology Co., Ltd., also referred to as Pukang Bio, is a biopharmaceutical manufacturer established in 2008. The company specializes in the research, development, production, and sale of polypeptide long-acting drug side chains and single-molecule polyethylene glycol (PEG) derivatives. Pukang Bio operates as a Contract Development and Manufacturing Organization (CDMO), providing services to healthcare and pharmaceutical companies worldwide, with sales markets in East Asia, Europe, North America, and South Asia.

The company has developed a polypeptide long-acting modifier platform that supplies various peptide side chain molecules and offers design, research, and documentation services. These products, including aliphatic alkane, MIPA, and cholesterol series, are utilized in drugs for conditions like GLP-1 and HIV to extend their half-life and improve patient compliance. Pukang Bio has also built an extensive library of small-molecule PEG derivative blocks, which are used in biomedical applications such as drug delivery, ADC conjugation, and to enhance the stability of nucleic acid drugs like siRNA. Its product portfolio includes advanced intermediates, excipients, LINKERs, and various amino acids and their derivatives.

Pukang Bio is a privately held, venture capital-backed company. It has secured multiple funding rounds, including a Series B in October 2023 and a Series B1 in June 2024, with investors such as IDG Capital, GL Ventures, and Mirae Asset Global Investments. To support its operations, the company has a 3,000-square-meter R&D center, a pilot-scale laboratory, and a 60,000-square-meter production base that complies with GMP standards.

Keywords: polypeptide side chains, drug delivery, PEG derivatives, biopharmaceuticals, CDMO services, long-acting drugs, peptide modifiers, GLP-1, small molecule PEG, nucleic acid drug delivery, pharmaceutical intermediates, venture capital-backed, life sciences, API manufacturer, excipients